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Research Article
Microvesicle Cargo of Tumor-Associated MUC1 to Dendritic
Cells Allows Cross-presentation and Specific Carbohydrate
Processing
Aurelia Rughetti1, Hassan Rahimi1, Francesca Belleudi2, Chiara Napoletano1, Federico Battisti1,
Ilaria G. Zizzari1, Morena Antonilli3, Filippo Bellati3, Hans H. Wandall4, Pierluigi Benedetti Panici3,
Joy M. Burchell5, Mara R. Torrisi2, and Marianna Nuti1
Abstract
Tumor-associated glycoproteins are a group of antigens with high immunogenic interest: The glycoforms
generated by the aberrant glycosylation are tumor-specific and the novel glycoepitopes exposed can be targets
of tumor-specific immune responses. The MUC1 antigen is one of the most relevant tumor-associated
glycoproteins. In cancer, MUC1 loses polarity and becomes overexpressed and hypoglycosylated. Changes in
glycan moieties contribute to MUC1 immunogenicity and can modify the interactions of tumor cells with
antigen-presenting cells such as dendritic cells that would affect the overall antitumor immune response. Here,
we show that the form of the MUC1 antigen, i.e., soluble or as microvesicle cargo, influences MUC1 processing
in dendritic cells. In fact, MUC1 carried by microvesicles translocates from the endolysosomal/HLA-II to the
HLA-I compartment and is presented by dendritic cells to MUC1-specific CD8þ T cells stimulating IFN-g
responses, whereas the soluble MUC1 is retained in the endolysosomal/HLA-II compartment independently by
the glycan moieties and by the modality of internalization (receptor-mediated or non–receptor mediated).
MUC1 translocation to the HLA-I compartment is accompanied by deglycosylation that generates novel MUC1
glycoepitopes. Microvesicle-mediated transfer of tumor-associated glycoproteins to dendritic cells may be a
relevant biologic mechanism in vivo contributing to define the type of immunogenicity elicited. Furthermore,
these results have important implications for the design of glycoprotein-based immunogens for cancer
immunotherapy. Cancer Immunol Res; 2(2); 177–86. 2013 AACR.
Introduction
Changes in glycosylation that occur during tumor transfor-
mation can profoundly affect the interactions between tumor
cells and the microenvironment with strong impact on the
overall antitumor immune response. The mucin MUC1 is one
of the most relevant tumor-associated glycoproteins; it is an
O-linked glycosylated transmembrane protein normally
expressed on the apical surface of epithelial cells, but aber-
rantly expressed in a broad spectrum of carcinomas. Upon
malignant transformation, MUC1 loses polarity and becomes
overexpressed and hypoglycosylated, revealing an immuno-
genic region of tandem repeats of 20 residues. The novel MUC1
glycoforms that arise carry shortened glycan moieties: Tn
(GalNAc), T (Galb1,3GalNAc), ST (NeuAca2, 3Galb1,3GalNAc),
and STn (NeuAca2,6GalNAc; ref. 1). These changes in the
glycosylation pattern impact MUC1 immunogenicity and the
interactions of tumor cells with the microenvironment (2). In
patientswith cancer, anti-MUC1 IgG responses are present and
correlate with the outcome of the disease (3). The anti-MUC1
CD8þ T-cell responses in patients with cancer are directed
mostly against the peptide epitopes in the MUC1 extracellular
domain (4). It is reasonable to think that in vivo glycoepitopes
displayed by the tumor-associated glycoforms are targets for
the antitumor response. In fact, the significant IgG immune
response in patients with cancer was shown to be directed
against the MUC1 glycoepitopes (5), and the binding of the
MUC1 glycopeptides to the MHC groove could induce T-cell
activation inmousemodels and in human studies in vitro (6–8).
In addition, the modality of uptake of MUC1 by antigen-
presenting cells (APC) in vivo can impact antigen presentation,
resulting in efficacious CD8þ- and IgG-mediated immune
responses or in CD4þ tolerizing responses (9). Recently, we
have demonstrated that alteredMUC1 glycosylation influences
its uptake by dendritic cells and modifies dendritic cell func-
tions. We have also demonstrated that MUC1-based
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Tn-peptide interacts with dendritic cells through the C-type
Lectin MGL (macrophage galactose-type C-type lectin) and is
translocated to the HLA-I compartment, thus indicating
that cross-processing for the MUC1 glycoantigen was possible
and size dependent (2, 10).
Together, these results offer evidence of the complexity of
MUC1 biology in its expression in tumor cells and its relation-
ship with the immune system. Understanding the intracellular
processing of the MUC1 glycoprotein and how the immuno-
genic glycoepitopes can be generated will inform the design of
dendritic cell–based vaccines targeting MUC1.
In this report, we show that independent of the glycosylation
profile of MUC1, antigen formulation is of crucial importance
both for cross-processing and for generating immunogenic
glycoepitope array. While the two recombinant soluble glyco-
proteins ofMUC1, the highly sialylated rST-MUC1 and the rTn-
MUC1 carrying only Tn glycans, are blocked in the endosomal/
HLA-II compartments, the TAA-MUC1 glycoforms, when deliv-
ered to dendritic cells by microvesicles, are processed in the
HLA-II and HLA-I compartments.
Microvesicles represent a novel vehicle of communication
between cells, which has just begun to be explored. Mem-
branes, cytosolic proteins, lipids, and RNA are transferred in
vivo via microvesicles in body fluids; these cargos possess
regulatory and biomarker functions (11). Microvesicles have
also been proposed as vehicles for antigen transfer. In vivo,
tumor cells shed antigens both in soluble form and associated
with microvesicles. Microvesicles carrying tumor antigens are
valid immunogens in mouse models enhancing the immuno-
genicity of soluble antigen (12) in in vitro human studies (13)
and in pilot vaccination studies (14).
Our results support the hypothesis that MUC1 immunoge-
nicity is strictly dependent on the form of the antigen and
suggest that microvesicle cargo of MUC1 should be preferred
in the design of glycoprotein-based immunogens for cancer
therapy.
Materials and Methods
MUC1 recombinant proteins
rST-MUC1 glycoprotein was generated by CHO-K1 cells
(ATCC CRL-9618) transfected with a MUC1-murine-IgG2a
fusion cDNA construct containing 16 tandem repeats (15).
The Fc region was removed by enterokinase treatment. The
cells were cultured in Iscove's modified Dulbecco's medium
(Hyclone) with 600 mg/mL of neomycin (Invitrogen) and were
kept in culture for no longer than 2 months.
rTn-MUC1 glycoprotein was produced in CHO-ldlD cells
(kindly provided by Prof. Henrik Clausen, University of Copen-
hagen) transfected with the same construct and cultured as
described above.
Exploiting the deficiency of UDP-Gal/UDP-GalNAc4-epim-
erase in these cells (16), culturing them with 1 mmol/L of
GalNAc yielded cells expressing soluble Tn-MUC1. MUC1
glycoproteins were purified from the culture supernatant by
anti-MUC1 monoclonal antibodies (mAb) affinity chromatog-
raphy after cleavage with enterokinase. mAb HMFG2 was used
for rST-MUC1 and mAb 5E5 (specifically reacting with MUC1
carrying Tn; ref. 17) for rTn-MUC1. The cells were never kept in
culture for more than 2 months. The pattern of glycosylation
on MUC1 was indicative of these cells.
Cell lines
DG75 lymphoblastoid cells (provided by Prof. P. Trivedi,
"Sapienza" University of Rome, Rome, Italy) were cultured as
described by Napoletano and colleagues (13). MUC1-DG75–
transfected cells were cultured in neomycin (1 mg/mL, Invi-
trogen). Before microvesicle production, DG75 and MUC1-
DG75 cells were analyzed for the expression of CD22, MUC1,
HLA-I-A2, HLA-DR, and CD86 by cytofluorimetry. Cells were
also tested for EBV (EBV PCR Kit, Abbott Molecular).
The breast cancer cell line T47D (ATCC-HTB-133) was
cultured in Dulbecco's modified Eagle medium (Hyclone) þ
10% fetal calf serum (Hyclone). All cell lines were tested for
mycoplasma before use (PlasmoTest, Invivogen).
Dendritic cell generation
Peripheral blood mononuclear cells of healthy donors were
isolated by Ficoll-Hypaque gradient (1,077 g/mL; Pharmacia
LKB). Monocytes were magnetically immunoselected (Milte-
nyi Biotech). Fifty ng/mL rhGM-CSF and rhIL4 (1,000 U/mL,
R&D Systems) were added to the cells in culture at day 0 and 2
to obtain immature dendritic cells (iDC). iDCs were collected
at day 5 and matured dendritic cells (mDC) were obtained by
incubating iDCs with rhIL-1b, IL-6, TNF-a (10 ng/mL each),
and prostaglandin E2 (1 mg/mL; R&D Systems) for 16 hours.
iDCs were used for the immunofluorescence studies; mDCs
were employed for stimulating CD8þ T cells.
Flow cytometry
MGL receptor on dendritic cells was detected using the mAb
anti-human MGL (125A10.03 clone, Dendritics) followed by
fluorescein isothiocynate (FITC)-conjugated goat anti-mouse
IgG (HþL; Jackson ImmunoResearchLaboratories). Afterwash-
ing, at least 1 104 events were evaluated using a FACSCalibur
flow cytometer running CellQuest software (BectonDickinson).
Microvesicle purification
Microvesicles were purified from ascites of patients with
ovarian cancer (stages III and IV; obtained after informed
consent) and from supernatants of DG75 and MUC1-DG75
cells as described (13). Ascites were centrifuged three times at
4C and ultracentrifuged (Type 35 rotor, Beckman Coulter)
2 at 4C (11,300 rpm/30 minutes; 35,000 rpm/1 hour).
The protein concentration was measured by Bradford assay
(Bio-Rad Laboratories). To generate microvesicles from the
MUC1-DG75 and DG75 cell lines, cells were cultured 3.5 105
cells/mL as previously described (13).
MUC1 internalization by dendritic cells
MGL iDCs were pulsed with rST-MUC1 or rTn-MUC1
glycoproteins (30 mg/mL; 12 hours; 37C) or with micro-
vesicles carrying MUC1 purified from ascites [MUC1-Ase-MVs
(microvesicles)] or fromMUC1-DG75 cells (MUC1-DG75-MVs;
500 mg/mL; 2 and 12 hours; 37C). ForMGL receptor-mediated
endocytosis, MGLþ dendritic cells were incubated with
rTn-MUC1 (10 mg/mL; 30 minutes on ice), washed, and incu-
bated (12 hours; 37C).
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Immunofluorescence microscopy
After MUC1 endocytosis, iDCs were cytospun (8  104
cells/sample) and fixed with cold acetone/methanol (1:1;
Carlo Erba Reagents). iDCs were incubated (45 minutes;
room temperature) with the anti-MUC1 mAb Ma552 (1:20,
Monosan), followed by FITC-conjugated goat anti-mouse F
(ab)2 (1:100; 30 minutes at room temperature). After wash-
ing, the samples were incubated with mAbs anti-Lamp-1
(E-5, Santa Cruz Biotechnology), anti-HLA-DR (L243 clone),
and rabbit polyclonal antibody anti-calreticulin (Stress-
gene). As secondary antibodies, Texas red–conjugated
goat anti-mouse (1:100) and anti-rabbit antibodies F(ab)2
(1:300; Jackson ImmunoResearch Laboratories) were used.
Unpulsed dendritic cells were used as negative control.
Fluorescence signals were visualized with an Axiovert 200
inverted microscope (Zeiss) using a 63 oil immersion
objective (numeric aperture: 1.4); cells were scanned in a
series of 0.5 mm sequential sections with an ApoTome
System (Zeiss) and images were all acquired by the digital
camera Axio CAM MRm (Zeiss; acquisition setting: average
2, filter for background noise: medium). Image analysis was
performed by the Axiovision software (Zeiss). Reconstruc-
tion of a selection of three central out of the total number of
the serial optical sections was shown in each figure. Quan-
titative analysis of the extent of colocalization of fluo-
rescence signals was performed using the KS300 3.0 Image
Processing System (Zeiss). The mean  SE percent of
colocalization was calculated analyzing a minimum of 30
cells for each treatment randomly taken from three inde-
pendent experiments. To visualize MUC1 glycoepitopes, the
following mAbs were used (Table 1): anti-MUC1 (Ma552
clone ref. 18), anti-ST-MUC1 (MY1E12 clone; ref. 19), anti-
T-MUC1 (2D9 clone), and anti-Tn-MUC1 (5E5 clone; ref. 20).
Quantitative analysis of the percentage of MUC1-positive
cells was assessed counting 100 cells per sample, randomly
observed in 10 microscopic fields from three experiments.
Results were expressed as mean values  SE. P values were
calculated using Student t test. Significance level was defined
as P < 0.05 (, P < 0.05; , P < 0.01; , P < 0.005).
CA15.3 assay
CA15.3 levels in total ascites, ultracentrifuged supernatants,
and vesicle fractions were determined by chemoluminescence
assay (Roche Diagnostic).
Western blotting
DG75 and MUC1-DG75 were lysed using the NP-40 solu-
tion (Biocompare) with phenylmethylsufonylfluoride (PMSF;
1 mmol/L; Sigma) and protease inhibitors (1; Sigma). Micro-
vesicles and cell lysates (30 mg/sample) were separated on
4%–12% SDS-PAGE and blotted onto nitrocellulose transfer
membrane (Schleicher and Schuell). Membranes were incu-
bated with anti-MUC1 Ma552 (1 hour at room temperature),
followed by anti-mouse Fc peroxidase-conjugated antibody
(1:20,000; Jackson ImmunoResearch; 1 hour at room temper-
ature). Protein bands were detected with enhanced chemi-
luminescence reagents (ECL Western Blotting Detection,
Amersham Biosciences).
Subcellular fractionation
iDCs were incubated with MUC1-Asc-MVs (500 mg/mL) or
rST-MUC1 (50 mg/mL; 12 hours; 37C), washed, and suspended
in ice-cold isotonic buffer (0.25 mol/L mannitol, 10 mmol/L
HEPES, 1 mmol/L LEGTA, 2% bovine serum albumin), with
protease inhibitors (1 mmol/L PMSF, 1 mg/mL aprotinin, and
1 mg/mL Leupeptin; Sigma). Cells were mechanically homo-
genized and centrifuged at 3,000 rpm. The supernatant was
further centrifuged at 11,000 rpm; the pellet, containing endo-
cytic/lysosomal compartments (P10 fraction), was collected
and stored at 80C until use, whereas the supernatant was
centrifuged at 33,000 rpm to isolate the cytoplasm (S20 frac-
tion). The protein concentration was measured by Bradford
assay (Bio-Rad).
ELISA assay
Flat-bottomed 96-well EIA/RIA plates (Corning Incorporat-
ed) were precoated overnight with P10 and S20 fraction (5
mg/well). Samples were incubated with the anti-MUC1 Ma552
(1 hour, 37C). Peroxidase-conjugated goat anti-mouse IgG
(HþL; 1:5,000, Jackson ImmunoResearch) was added to the
wells, followed by chromogen addiction (5 mg O-phenylene-
diamine, Citrate phosphate buffer 10 mL, 30% H2O2 10 mL;
Sigma-Aldrich). The absorbance was measured at 492 nm.
ELISpot
MUC1-enrichedCD8þTcellsderived fromthreeMUC1(159-167)
(SAPDNRPAL; ref. 21) vaccinated ovarian cancer patients were
cocultured with autologous mDCs pulsed with MUC1-DG75-
MVs, DG75-MVs (100 mg/105 iDCs), or MUC1(159-167) peptide
(30 mg/mL) in the anti-IFN-g precoated (1:200; Pharmingen)
ELISpot plates (Millipore) overnight. Cytokine release was
detected with biotinylated anti-IFN-g antibody (Pharmingen;
1:250, 2 hours) revealed with streptavidin-alkaline phosphatase
(Pharmingen) (1:1,000, 100 mL/well, 1 hour) and chromogen
substrate. Spots were counted using the ImmunoSpot Image
Analyzer (Aelvis).
Results
Tumor-associated glycoprotein MUC1 is blocked in the
endolysosomal/HLA-II compartments in dendritic cells
Uptake of tumor-associated glycoproteins and their
intracellular routing in dendritic cells were studied utiliz-
ing two distinct glycan forms, Tn (GalNAc) and ST
Table 1. Anti-MUC1 mAbs employed in the
study
mAb
Glycoepitope
recognized
Glycan
structure
Ma552 All MUC1 glycoforms
MY1E12 ST-MUC1 -^*-&-Ser/Thr
2D9 T-MUC1 *-&-Ser/Thr
5E5 Tn-MUC1 &-Ser/Thr
& GalNAc * Galb ^ NeuAc
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(NeuAca2,3Gal 1,3GalNAc) of the recombinant tumor-
associated MUC1 glycoprotein (Fig. 1). The rST-MUC1 was
produced by expressing the extracellular domain of MUC1
containing 16 tandem repeats in CHO-K1, whereas the rTn-
MUC1 glycoform was produced in CHO-ldlD cells. The
CHO-ldlD cells lack UPD-Gal/UDP-GalNAc4-epimerase
that results in their inability to synthesize Galactose and
GalNAc. Therefore, in the absence of ST6GalNAc-I, they
produce O-linked glycoproteins carrying only Tn (16).
To investigate whether diversity of glycan moieties on the
MUC1 backbone could modify its processing, the intracellular
routing of rST- and rTn-MUC1 glycoproteins via non-receptor–
mediated endocytosis was evaluated using MGL-negative
iDCs by immunofluorescence after 12 hours (Fig. 2, columns
1–6). As negative control, unpulsed iDCs were employed: no
MUC1 staining was detected (data not shown).
rST-MUC1 glycoprotein (green; Fig. 2, column1–3) appeared
to be distributed in discrete granules along the plasma mem-
brane and in the cytoplasm. Colocalization with specific
compartment markers (yellow) was performed employing
calreticulin, HLA-II-DR, and Lamp-1 molecules as markers for
HLA-I, HLA-II, and endolysosomal compartment, respectively
(red). A strong association with the endolysosomal compart-
ment (36%) and at a lower extent with the HLA-II compart-
ment (22,6%) could be observed, whereas a rare association
with calreticulin staining was quantified (15,8%). Similar to the
staining pattern observed for the rST-MUC1, rTn-MUC1
(green) localized into discrete dots distributed at the periphery
of the iDCs (Fig. 2, columns 4–6). Quantification of the asso-
ciation between rTn-MUC1 and the compartment markers
revealed infrequent colocalization for the calreticulin positive
compartment (11%), some association with the HLA-II com-
partment (29%) and again a strong association with the
endolysosomal compartment marker Lamp-1 (41%). These
results indicated that following non–receptor-mediated inter-
nalization, the glycosylation profile of MUC1 did not influence
its intracellular routing in APCs, i.e., both MUC1 glycoforms
(rST and rTn) weremostly accumulated in the endolysosomal/
HLA-II compartment with no delivery to the HLA-I compart-
ment. The Tn-MUC1 glycoform, also internalized by iDCs upon
binding to the C-type lectin MGL (2), was employed as exper-
imental control (Fig. 2, columns 7–9).
rTn-MUC1 endocytated via MGL was distributed to small
dotted structures (green) below the plasma membrane. Colo-
calization studies indicated a significant increase in the asso-
ciation with the Lamp-1 marker (65%) as compared with the
non–receptor-mediated internalization, whereas a similar
association pattern was found for the HLA-II and calreticulin
(32% and 11%, respectively). These results indicated that
MGL receptor-mediated endocytosis significantly increased
the delivery of the MUC1 antigen to the endolysosomal com-
partment without affecting the delivery to the HLA-II com-
partment. A very low level of MUC1 delivery of the antigen to
the calreticulin-positive compartment was observed.
MUC1 associated with microvesicles is cross-processed
in the HLA-I compartment in dendritic cells
The presence of MUC1 glycoprotein was analyzed in the
ascites of 5 ovarian cancer patients using the standardized
serum CA15.3 assay that quantifies circulating tumor-associ-
ated MUC1 (Fig. 3A). In addition, MUC1 was also quantified in
the microvesicles (MUC1-Asc-MVs) and in the supernatants
obtained after the ultracentrifugation of the ascites. MUC1was
found at high levels in all the ascites examined and at lower
concentrations in the other two fractions. Western blot anal-
ysis confirmed the presence of MUC1 on the microvesicles
Figure 1. Structure of the
recombinant MUC1 glycoproteins.
The protein backbone of theMUC1
recombinant protein is depicted
indicating the five possible
O-glycosylation sites for each
tandem repeat. The O-glycan
composition of the rTn-MUC1
produced inCHO-ldlDcells and the
rST-MUC1 produced in CHO-K1
cells is reported.
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purified from the ascites (Fig. 3B). The purified Asc-MVs
carrying MUC1 were used to pulse iDCs, and the MUC1
intracellular routing was analyzed by immunofluorescence
after 2 and 12 hours (Fig. 4A). After 2 hours of pulsing, MUC1
carried bymicrovesicles (green) was found in discrete granules
distributed throughout the cytoplasm of cells, whereas no
MUC1 staining was detected in the unpulsed iDCs (data not
shown). Strong association of MUC1 was found with Lamp-1
and HLA-II-DR staining (70% and 62%, respectively), whereas
no colocalization was found with calreticulin (7%). These
results clearly showed that MUC1 carried by microvesicles
from ascites was delivered to the endolysosomal and HLA-II
compartments in a higher percentage compared with the
non–membrane-bound forms of MUC1.
After 12 hours, a striking difference was observed: MUC1
staining was mainly cytoplasmic and distributed along the
nuclear membrane, with a significant increase in the associ-
ation with calreticulin (38%) and a significant decrease in the
association with Lamp-1 (51%). These results suggested that
MUC1 carried by microvesicles was transferred from the
endolysosmal to the HLA-I compartment. Surprisingly, MUC1
and HLA-II-DR scarcely colocalized in a significant manner
(8%). This result could be explained by the accumulation of
MUC1 in the intracellular compartments combined with the
translocation of the HLA-II-DR to the plasma membrane after
12 hours of incubation of iDCs (Supplementary Data, Supple-
mentary Fig. S1).
The presence of MUC1 in both the cytoplasm and the
vesicle/membrane fractions of iDCs pulsed with MUC1-
Asc-MVs (Fig. 4B) confirmed that MUC1 carried by micro-
vesicles was delivered to the HLA-I compartment through
the cytoplasm.
Figure 2. Tumor-associatedMUC1glycoproteins are blocked in the endolysosomal compartment. Intracellular localization ofMUC1 in iDCsand its distribution
in the intracellular compartments after non–receptor-mediated endocytosis of rST-MUC1 or rTn-MUC1 (columns 1–3 and 4–6, respectively) and MGL
receptor-mediated endocytosis of rTn-MUC1 (column 7–9) was visualized by immunofluorescence staining after 12 hours of internalization employing the
anti-MUC1 mAb Ma552 (green) combined with antibodies specific for distinct compartment markers (red, in particular, anticalreticulin polyclonal rabbit
antibody for ER (first row), anti-HLA-DR (HLA-II compartment, second row), and anti-Lamp-1 (endolysosomal compartment, third row). The percentage of
colocalization (yellow) was calculated analyzing a minimum of 30 cells for each treatment randomly taken from three independent experiments. Results
are expressed as mean values  SE in histograms. Magnification, 63; Bar, 10 mm. , P < 0.005 versus the corresponding rST-MUC1 and rTn-MUC1
pulsed MGL iDCs.
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MUC1 carried by microvesicles is cross-presented by
dendritic cells to MUC1-specific CD8þ T cells inducing
IFN-g production
Antigen translocation to the HLA-I compartment in den-
dritic cells is required but not sufficient for antigen cross-
presentation. To evaluate whether MUC1 was cross-pre-
sented, mDCs pulsed with MUC1 carried by microvesicles
were analyzed for their capacity to activate MUC1-specific
CD8þ T cells. The MUC1159-167 peptide was employed to
expand MUC1-specific CD8þ T cells from patients with
breast cancer, who have received MUC1159-167 peptide vac-
cination (LITRM/DIMIGE05/01, Visconti and colleagues,
Manuscript in preparation).
The lymphoblastoid cell line DG75 was transfected with
cDNAencoding the full-lengthMUC1 containing seven tandem
repeats (MUC1-DG75) and microvesicles carrying MUC1
(MUC1-DG75-MVs) were purified from the supernatant of the
transfected cell line (Supplementary Data, Supplementary Fig.
S2A–S2C). Autologous mDCs were pulsed with MUC1-DG75-
MVs or microvesicles purified from the untransfected DG75
cell line (DG75-MVs). These cells were used to stimulate
enriched MUC1159-167specific CD8þ T cells. IFN-g was highly
produced by T cells only in response to mDCs pulsed with
MUC1-DG75-MVs, but not to mDCs pulsed with DG75-MVs
(Fig. 4C). IFN-g production was also induced when T cells were
stimulated with autologous mDCs pulsed with MUC1159-167
peptide, whereas mDCs pulsed with the rST-MUC1 glycopro-
tein (30 mg/mL) did not induce any response (data not shown).
These results showed that MUC1 carried by microvesicles was
cross-presented to T cells.
MUC1 associated with microvesicles is differentially
deglycosylated during processing
The evidence that MUC1 associated with microvesicles was
delivered to the calreticulin/HLA-I compartments and cross-
presented to CD8þ T cells prompted us to further investigate
the processing of MUC1 analyzing the exposure of specific
glycosylated epitopes. The intracellular processing of MUC1
was studied in iDCs pulsed for 12 hours with rST-MUC1 or the
sialylated MUC1-DG75-MVs, both exclusively carrying ST-
MUC1 glycoform as probed with the mAbs recognizing the
specific MUC1 glycoepitopes, i.e., ST-MUC1, T and Tn MUC1
(mAb My1E12, 2D9 and 5E5, respectively; Supplementary Fig.
S2D) and as confirmed by neuraminidase treatment (data not
shown).
When dendritic cells were pulsed with MUC1-DG75-MVs
(Fig. 5, first row), 95% of the cells showed the presence of ST-
MUC1 glycoform localized in granules distributed in the entire
cytoplasm. ST-MUC1 carried by microvesicles was further
processed exhibiting T (18%) and Tn-glycoforms (45%), which
were associated with intracellular small dots in the cytoplasm.
iDCs pulsed with rST-MUC1 glycoprotein (Fig. 5, second
row) displayed reduced staining intensity for eachmAb tested,
indicating a significant decrease in the percentage of positive
cells. In fact, only 60% of the cells showed that the ST-MUC1
glycoform was associated with the small vesicles localized just
under the plasma membrane. T-MUC1 and Tn-MUC1 glyco-
forms were totally undetectable or extremely scarce (T-MUC1
< 3%; Tn-MUC1 5–8%). The absence of these glycoforms is
probably due to the retention of the rST-MUC1 in the endo-
somal compartment without further processing. The MUC1-
overexpressing breast cancer cell line T47D was used as a
positive control (Fig. 5, third row). These results suggested that
the processing of MUC1 transferred to dendritic cells by
microvesicles was accompanied by the deglycosylation pro-
cess, thus unmasking novel MUC1 glycoepitopes such as the
T and Tn-MUC1.
Discussion
During cancer transformation, several O-glycosylated pro-
teins are overexpressed and exhibited aberrant cancer-asso-
ciated truncated glycans. This change in glycosylation exposes
de novo tumor-specific and immunogenic glycoepitopes (22).
Furthermore, changes in the surface O-glycosylation impact
the interactions with APCs, as previous studies have shown
that selected glycans can be used as efficient tools for dendritic
cell targeting in cancer immunotherapy (23, 24).
Several O-glycoproteins are used as tumor markers, how-
ever, very few of these have been considered for cancer
immunotherapy. In fact, it is believed that large O-glycoanti-
gens induce mostly humoral and CD4þ responses, and not
antigen-specificCD8þTcells. However, it is clear that in cancer
Figure 3. Tumor-associated
MUC1 is present in ovarian cancer
ascites, both associated with
microvesicles and in soluble form.
A, MUC1 was detected in ovarian
cancer ascites, in the soluble and
vesicle fractions after
ultracentrifugation by CA15.3
assay. Results (IU/mL) are plotted
as histograms (light gray, ascites;
dark gray, supernatant fraction;
black, microvesicle fraction).
B, Western blot analysis
of MUC1-Asc-MVs, one
representative sample out of five is
shown. Microvesicles derived from
DG75 and MUC1-DG75 cell lines
are also shown as negative and
positive controls, respectively.
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patients specific IgG immune responses and CD8þ T-cell–
mediated responses have been detected against tumor-asso-
ciated O-glycoantigens such as CEA and MUC1, suggesting
that these molecules are cross-presented in humans (25).
These immune responses are protective and associated with
favorable prognosis (26).
In carcinomas that express MUC1, the tumor-associated
glycoforms of MUC1 have been shown to be immune targets
in vivo (27). In patients with cancer, CD8þ T cells directed
against MUC1 peptide epitopes were detected before and after
vaccination (28–30), and the IgG auto-antibodies against spe-
cific tumor-associated glycoforms were found in patients with
cancer with early-stage disease (5, 31).
Early work showed that MUC1 following internalization is
blocked in the endolysosomal compartment of dendritic cells
(9), suggesting that only a tolerizing CD4þ T-cell response
could be generated against this glycoantigen. However, this
study lacked the proper information on the glycan composition
and, because the carbohydrate moieties decorating the MUC1
peptide backbone affect the uptake by dendritic cells (2), we
speculated that the glycosylation profile could also modify the
intracellular processing. Two distinct recombinant MUC1
glycoproteins, both tumor associated, were employed to test
this hypothesis: the highly sialylated rST-MUC1, mostly carry-
ing ST-O–linked glycan (85%) and the rTn-MUC1 carrying only
Tn-glycans. rST-MUC1 exerts immunosuppressing effects on
dendritic cell differentiation (32), promotes tumor growth (33),
and no IgG specific response against the ST-MUC1 glycoform
was detected in patients with cancer (34). On the other hand,
Tn-MUC1 is immunogenic in mouse models (17, 20) and is a
target of a specific IgG immune response in patients with
cancer (5).
Despite the different immunogenicity, both rST-MUC1 and
rTn-MUC1 were accumulated mostly in the endolysosomal
compartment of iDCs after endocytosis. This indicates that the
O-glycan profile does not influence MUC1 intracellular proces-
sing. MGL receptor-mediated endocytosis of the Tn-MUC1
glycoform induced a significant increase ofMUC1 accumulation
Figure 4. MUC1 carried by
microvesicles is transported to the
HLA-I compartment in dendritic
cells and is cross-presented to
MUC1-specific CD8þ T cells. A,
intracellular localization ofMUC1 in
iDCs pulsed with MUC1-Asc-MVs
(2- or 12-hour incubation, column
1–3 and 4–6, respectively). MUC1
staining in green (mAb Ma552).
Compartment marker staining in
red: anti-calreticulin mAb for ER
membranes (first row), anti-HLA-II-
DR mAb (HLA-II compartment,
second row), polyclonal Ab anti-
Lamp-1 (endolysosomal
compartment, third row). Results
are expressed as mean values 
SE in histograms; percentage of
colocalization (yellow) was
calculated analyzing a minimum of
30 cells for each treatment
randomly taken from three
independent experiments.
Magnification, 63, Bar,
10 mm. , P < 0.05 or , P < 0.005
versus the corresponding iDCs
pulsedwithMUC1-MVs for 2 hours
at 37C; B, Detection of MUC1
molecule in the cytosol and
membrane fractions (gray and
black histograms, respectively) of
iDCs pulsed with MUC1-Asc-MVs
by ELISA. C, IFN-g ELISpot to
evaluate the cytokine secretion by
MUC1-specific enriched CD8þ T
cells in response to mDCs pulsed
with DG75-MVs (black histogram);
MUC1-DG75-MVs (white
histogram) and MUC1(159-167)
peptide (gray histogram).
Results are representative of one
patient out of three.
TAA-MUC1 Cargo in Microvesicles Is Cross-presented by Dendritic Cells
www.aacrjournals.org Cancer Immunol Res; 2(2) February 2014 183
on May 6, 2014. © 2014 American Association for Cancer Research. cancerimmunolres.aacrjournals.org Downloaded from 
Published OnlineFirst October 28, 2013; DOI: 10.1158/2326-6066.CIR-13-0112-T 
in the endolysosomal compartment but no cross-processing in
the HLA-I compartment was observed. These results are in
agreement with other studies showing that the presence of Tn
residues on the antigen increased antigen uptake by dendritic
cells and activation of CD4þ-mediated T-cell response, but it
failed to induce CD8þ T-cell–mediated response in animal
models (35). Cross-processing of MUC1 in dendritic cells was
observed only when small synthetic glycopeptides were
employed, suggesting that the shortening of the size of the
antigen could be a way to override the block in processing
(2, 36). However, in vivo, only the full-length MUC1 is available
to the host immune system and indeed MUC1-specific CD8þ
T cells were found in patients with cancer (4, 37). We then
hypothesized that other mechanisms of uptake that were gly-
cosylation independent could occur inducing MUC1 epitope
cross-presentation.
In vivo, antigens are released by the cells as soluble mole-
cules as well as associatedwithmicrovesicles. These organelles
are extremely heterogeneous in size, lipid composition, and
biogenesis. Release of microvesicles has been regarded as an
efficient way to deliver molecular signals into the microenvi-
ronment, overcoming cell–cell contact (38, 39). Moreover,
tumor antigen-associated microvesicles have been shown to
enhance the immunogenicity of soluble antigen (12), and to
induce CD8þ T-cell responses in in vitro human studies (13)
and in pilot vaccination studies (14).
MUC1 bound to themicrovesicles is released by cancer cells,
as we have detected in ovarian ascites. Uptake ofMUC1 carried
by microvesicles resulted in strong MUC1 accumulation in the
endolysosomal and HLA-II compartments after 2 hours of
incubation followed by the translocation of the antigen to the
HLA-I compartment after 12 hours of incubation. These results
showed for the first time that a large and highly glycosylated
antigen such as MUC1 is cross-processed by dendritic cells
when delivered through microvesicles. Several cellular
mechanisms have been proposed to explain the uptake and
Figure 5. MUC1 carried by
microvesicles undergoes
deglycosylation in iDCs. MUC1
staining in iDCspulsedwithMUC1-
DG75-MVs (first row) or rST-MUC1
glycoprotein (second row; 12-hour
incubation). First column, mAb
MY1E12 (anti-ST-MUC1); second
column, 2D9 (anti-T-MUC1); third
column, 5E5 (anti-Tn-MUC1).
T47D cells were positive control for
mAb reactivity (third row).
Magnification, 63; Bar, 10 mm.
Carbohydrate residues are
schematically represented.
Percentage of positive dendritic
cells for each mAb were plotted as
histograms (gray, anti-ST-MUC1;
dark gray, anti-T-MUC1; black,
anti-Tn-MUC1). , P < 0.01 versus
the corresponding iDCs pulsed
with MUC1-DG75-MVs.
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internalization of microvesicles by dendritic cells: macro-
pinocytosis, and membrane fusion, ligand-receptor–mediat-
ed endocytosis. Also, the type of microvesicles and the
acceptor cell are critical aspects in deciphering the inter-
nalization route of the transported antigen (40). In our
system, translocation of MUC1 to the calreticulin-positive
compartment was time dependent, implying intracellular
transport of MUC1 from microvesicles purified from ovarian
ascites and from microvesicles obtained from a MUC1-
transfected cell line. These observations prompted us to
test whether cross-processing resulted in cross-priming of
MUC1 epitopes. Functionally, mDCs primed by MUC1-MVs
were able to stimulate IFN-g production of enriched CD8þ T
cells, specific for the MUC1159-167 peptide epitope (21). So far,
MUC1-specific CD8þ T cells have been induced employing
peptide, RNA pulsed dendritic cells, or tumor cell–dendritic
cell fusion (37, 41, 42). This is the first time to our knowledge
that the full-length MUC1 glycoprotein is able to activate
MUC1-specific CD8þ T cells. Indeed, previous in vitro stu-
dies have shown that the APC machinery in dendritic cells
was competent to generate HLA-I–restricted MUC1 epitopes
employed as substrates to the MUC1-based glycopeptides
carrying distinct carbohydrate moieties (7, 43). The possi-
bility for a glycoantigen as large as MUC1 to be processed
and cross-presented opens the question about the intracel-
lular fate of the carbohydrate moieties associated with the
protein backbone. In our study, uptake and processing of ST-
MUC1 resulted in the cytoplasmic appearance of T-MUC1
and Tn-MUC1 glycoepitopes as detected by specific mAbs
only if the glycoprotein was delivered by microvesicles,
suggesting that the processed antigen underwent deglyco-
sylation, thus generating novel immunogenic glycoepitopes.
In summary, we have shown that MUC1 tumor-associated
antigen after internalization accumulated in the endosomal/
lysosomal compartments independently of its glycosylation
profile and by receptor-mediated endocytosis. This block was
overridden when MUC1 was delivered to dendritic cells
throughmicrovesicles and translocated to the HLA-I compart-
ment, inducing antigen cross-presentation leading to dendritic
cells capable of activating MUC1-specific CD8þ T cells. In
addition, microvesicle-mediated transfer of the sialylated
MUC1 glycoform to dendritic cells mediated the de novo
appearance of the shorter T and Tn-MUC1 glycoepitopes.
Transfer to dendritic cells of large glycoproteins by micro-
vesicles may be a relevant biologic mechanism in vivo that
contributes to shape the immunogenicity of tumor-associated
glycoantigens and to increase the complexity of the tumor
glycopeptidome. These results have important implications for
the design of glycoprotein-based immunogens for cancer
immunotherapy.
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